Guggenheim Adjusts Price Target on Amgen to $435
Guggenheim maintained its Neutral rating on Amgen while increasing its price target from $378 to $435.
Stocks · News reference
Amgen Announces Positive Phase 3 Clinical Results and FDA Labeling Update
Amgen reported that its Phase 3 OASIZ-301 study for dazodalibep met its primary endpoint and its Phase 3 TEPEZZA study in Japanese patients met primary endpoints, while the FDA approved updated labeling for IMDELLTRA.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Neutral on Amgen, Raises Price Target to $435
Amgen Announces Real-World Study Results for Repatha
Amgen reported new real-world study data indicating that its cholesterol-lowering medication Repatha (evolocumab) outperformed ezetimibe in reducing heart disease risk.
Amgen Announces Results From Large Real-World Study Showing Treatment With Repatha Reduced Risk Of Fatal Or Nonfatal Heart Attacks By 20% Compared With Ezetimibe In People With ASCVD And Prior Statin Use
Amgen Price Target Raised by Analyst
An analyst has increased the price target for Amgen Inc. shares to $400.00 from $345.00.
Citigroup Maintains Neutral on Amgen, Raises Price Target to $465